TMX group

- patents cover human health technologies in U.S. and EU -

BELLEVILLE, ON, Nov. 2 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that it has been granted three new patents for its core proprietary
Mycobacterial Cell Wall-DNA Complex (MCC) and the related oligonucleotides.
The President & CEO of Bioniche Life Sciences Inc., Graeme McRae, noted,
"Bioniche takes its patent portfolio very seriously. We have more than 300
approved patents or pending patent applications in progress, and we are
constantly adding more. This ensures the maximum opportunity for returns on
marketed products."

MCC Patent

The Company has been granted a patent in the U.S. entitled "Hyaluronic
acid in the treatment of cancer" (U.S. Patent No. 7125858), inventors Dr.
Nigel C. Phillips and Dr. Mario C. Filion, Bioniche Therapeutics.
The patent has composition and methods claims covering the use of
hyaluronic acid in combination with the Company's proprietary MCC and
oligonucleotide technologies for the treatment of cancer. The patent also
covers the use of hyaluronic acid with the anticancer agent tamoxifen for the
treatment of cancer.
The coverage of cancer types that can be treated is very broad and
includes squamous cell carcinoma, fibrosarcoma, sarcoid carcinoma, melanoma,
mammary cancer, lung cancer, colorectal cancer, renal cancer, osteosarcoma,
cutaneous melanoma, basal cell carcinoma, pancreatic cancer, bladder cancer,
brain cancer, ovarian cancer, prostate cancer, leukemia or lymphoma.

About MCC

Mycobacterial Cell Wall-DNA Complex (MCC) is a composition prepared from
from Mycobacterium phlei, a saprophytic mycobacteria. MCC has immune
stimulatory as well as apoptosis (programmed cell death) inducing activity
against cancer cells. A formulation of MCC is currently under development for
the treatment of high-grade non-invasive bladder cancer.

Oligonucleotide Patents

The Company has also been granted two additional patents focusing on
olionucleotides, one in Europe and one in the U.S.
The European patent, "Conformation-Activity Relationship of
Apoptosis-Inducing Phosphodiester Oligonucleotides" (EP patent no. 1448986),
describes the invention of a computer-based method to predict the anticancer
activity of oligonucleotides. The inventors are: Dr. Nigel C. Phillips, Dr.
Mario C. Filion, Dr. Sidney Holan and Dr. StDephanie Reader, Bioniche
Therapeutics.
The U.S. patent, "Oligonucleotide compositions and their use to induce
differentiation of cells" (US patent no. 7087586), is based on method claims
for 3'-OH, 5'-OH, chemically unmodified synthetic phospiodiester
oligonucleotide covering use in both animals and humans with disease
associated with insufficient differentiation of cells or to increase
differentiation of pluriopotent cells. Such disease includes leukemia and
lymphoma, among others. The inventors are: Dr. Mario C. Filion and Dr. Nigel
C. Phillips, Bioniche Therapeutics.
The Company plans to develop this platform through additional
pre-clinical research in the immunomodulatory and anti-cancer areas and is
actively seeking opportunities to partner the technology for further
development.

About the Oligonucleotide Technology Platform

In 2000, Bioniche announced the discovery of a new class of molecules
with potential anticancer and immune modulatory activity, trademarked by the
Company as "Oligomodulator(TM)". This new class of molecules, which have
potential clinical applications in the fields of cancer and immune modulation,
are composed of short non-antisense DNA oligonucleotides with novel
pharmacological activities.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
188 skilled personnel and has three principal operating divisions: Human
Health, Animal Health, and Food Safety. The Company's primary goal is to
develop proprietary cancer therapies supported by revenues from marketed
products in human and animal health. For more information, please visit
www.Bioniche.com.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

%SEDAR: 00013159E